What overseas decisions could mean for Australia
Overseas regulatory decisions on psychedelic medicines, the Australian step each one corresponds to, and how long comparable medicines have taken to get from one to the other.
This page holds reference classes, base rates and open questions. It does not predict what any person can access, and it is not advice.
Every row was last checked against its source on .
Australia moved first on scheduling
Scheduling decides who may lawfully prescribe a substance. Registration decides whether a product has been evaluated and entered on the Australian Register of Therapeutic Goods. Subsidy decides whether the PBS or Medicare pays. Australia is ahead of the United States on the first and has taken neither of the other two steps.
- 3 February 2023The TGA announced final decisions to amend the Poisons Standard for psilocybine and MDMA. TGA questions and answers
- 1 July 2023Psilocybine for treatment-resistant depression and MDMA for post-traumatic stress disorder became Schedule 8 when prescribed by a psychiatrist approved under the Authorised Prescriber scheme. Every other use stayed in Schedule 9. TGA questions and answers
- 18 August 2026The TGA counted 61 active Authorised Prescribers for psilocybine and 61 for MDMA. TGA, FOI 27-3566
- 20 November 2026In the United States both substances are in Schedule I, and the FDA has approved neither. In Australia a search of the ARTG for psilocybine returns no entries, and the TGA describes both as unapproved medicines. eCFR, 21 CFR 1308.11
Overseas milestones and the Australian equivalent
Each overseas event sits beside the Australian step it corresponds to. Registration, subsidy, scheduling and access schemes are kept as separate reference classes.
8 of 8 milestones
| Overseas event | Status | Australian equivalent | Status in Australia |
|---|---|---|---|
| FDA, United States · 5 Mar 2019Spravato nasal spray approved (original approval, NDA 211243).Treatment-resistant depressionDrugs@FDA, NDA 211243 (checked 20 Nov 2026) | Approved | TGA registration of Spravato on the ARTG. | Registered on 9 March 2021, two years after the FDA approval.TGA decision summary: Spravato (checked 20 Nov 2026) |
| FDA, United States · 5 Mar 2019Approval, the point from which public and private payers could consider cover. The United States has no single national listing step.Treatment-resistant depressionDrugs@FDA, NDA 211243 (checked 20 Nov 2026) | Approved | PBS listing after a PBAC recommendation. | Listed on the PBS on 1 May 2025, after the PBAC recommended it in December 2024. Earlier submissions in 2021, 2022 and 2023 were not recommended and one in July 2024 was deferred.PBS medicine status: esketamine (checked 20 Nov 2026) |
| FDA, United States · 8 Aug 2024Complete response letter for midomafetamine capsules (NDA 215455, Lykos Therapeutics): not approved in its submitted form.Post-traumatic stress disorderFDA complete response letter, NDA 215455 (checked 20 Nov 2026) | Not approved. A resubmission was reported in August 2026 by a third party; no FDA record or company statement confirming it was found. | An application to register an MDMA product on the ARTG. | No MDMA medicine is on the ARTG. It is an unapproved medicine.TGA: accessing MDMA and psilocybine as a psychiatrist (checked 20 Nov 2026) |
| FDA, United States · 9 Nov 2026Compass Pathways announced it had completed its new drug application for COMP360.Treatment-resistant depressionCompass Pathways media release, 9 November 2026 (checked 20 Nov 2026) | Submitted, by the company's account. No FDA decision. | An application to register a psilocybin product on the ARTG. | No psilocybin medicine is on the ARTG (a search for psilocybine returns no entries). It is an unapproved medicine.ARTG search: psilocybine (checked 20 Nov 2026) |
| FDA, United States · 5 Jan 2026Usona Institute's phase 3 trial (NCT06308653) reached primary completion; the registry lists it as active, not recruiting, with no results posted.Major depressive disorderClinicalTrials.gov, NCT06308653 (checked 20 Nov 2026) | Phase 3. No application confirmed by the sponsor or the FDA. | An application to register a psilocybin product on the ARTG. | No psilocybin medicine is on the ARTG. It is an unapproved medicine.TGA: accessing MDMA and psilocybine as a psychiatrist (checked 20 Nov 2026) |
| FDA, United States · 9 Nov 2026Definium Therapeutics (formerly MindMed) reported topline results from two phase 3 trials of DT120 and said it plans to file a new drug application in the first half of 2027.Generalised anxiety disorderDefinium Therapeutics third quarter 2026 results (checked 20 Nov 2026) | Phase 3. No application filed. | Scheduling and registration of lysergide. | Lysergide is not on the ARTG (a search returns no entries). The Australia page records its place in the Poisons Standard.ARTG search: lysergide (checked 20 Nov 2026) |
| DEA, United States · 20 Nov 2026Psilocybin and MDMA are listed in Schedule I of the Controlled Substances Act regulations (21 CFR 1308.11), as read on the check date.All useseCFR, 21 CFR 1308.11 (checked 20 Nov 2026) | Schedule I. Unchanged. | Scheduling in the Poisons Standard. | Since 1 July 2023 psilocybine (for treatment-resistant depression) and MDMA (for post-traumatic stress disorder) are in Schedule 8 when prescribed by an authorised psychiatrist. The decision was announced on 3 February 2023. Other uses stay in Schedule 9.TGA: re-scheduling of psilocybin and MDMA, questions and answers (checked 20 Nov 2026) |
| Health Canada, Canada · 5 Jan 2022Regulations (SOR/2021-271) restored the option for practitioners to request restricted drugs, which include psilocybin and MDMA, through the Special Access Program.Serious or life-threatening conditions, case by caseCanada Gazette, Part II, volume 156, number 1 (checked 20 Nov 2026) | In force. Requests are decided one patient at a time. | The Authorised Prescriber scheme for psychiatrists. | Open since 1 July 2023 for psilocybine and MDMA, for one condition each. The TGA counted 61 active Authorised Prescribers for each as at 18 August 2026.TGA, FOI 27-3566, data current to 18 August 2026 (checked 20 Nov 2026) |
How long has it taken before?
Reference class: novel psychiatric and sleep medicines first approved by the FDA from 2013 onward. 13 medicines, each date linked to its source.
FDA approval to ARTG entryARTG entry to PBS listingNo ARTG entry so far
Scale: 0 to 8 years since the FDA's original approval. Thin bars show time elapsed without an ARTG entry up to the check date.
FDA approval to ARTG entry
- On the ARTG
- 6 of 13
- Median lag
- 1.9 years
- Middle half of lags
- 1.6 to 2.2 years
- Within 1 year
- 1 of 13 (8%)Kaplan-Meier 8%
- Within 2 years
- 3 of 13 (23%)Kaplan-Meier 23%
- Within 5 years
- 5 of 8 (63%)Kaplan-Meier 39%
All 13 medicines.
FDA approval to PBS listing
- PBS-listed
- 3 of 10
- Median lag
- 6.0 years
- Middle half of lags
- 4.1 to 6.1 years
- Within 1 year
- 0 of 10 (0%)Kaplan-Meier 0%
- Within 2 years
- 0 of 10 (0%)Kaplan-Meier 0%
- Within 5 years
- 1 of 5 (20%)Kaplan-Meier 11%
10 medicines: three registered ones whose PBS status was not checked are left out.
Method. The lag is the time from the FDA's original approval to the first ARTG entry, or to the first PBS listing, in years of 365.25 days. The median and the middle half (25th to 75th percentile) describe only the medicines that reached that step. The shares within 1, 2 and 5 years count a medicine with no entry as not reached, and include only medicines the FDA approved at least that many years before 20 November 2026, so a recent approval is not counted before it has had the full time. The Kaplan-Meier figure uses all the medicines and treats those with no entry as still waiting on the check date. The two methods differ at 5 years because none of the five medicines approved since 2022 has an ARTG entry.
| Medicine | FDA approval | ARTG entry | Lag | PBS listing | Lag from FDA |
|---|---|---|---|---|---|
| VortioxetineBrintellix (Trintellix in the US) · Major depressive disorder | 30 Sept 2013 | 31 Mar 2014 | 0.5 y | Not checked | – |
| SuvorexantBelsomra · Insomnia | 13 Aug 2014 | 16 Nov 2016 | 2.3 y | Not checked | – |
| BrexpiprazoleRexulti · Schizophrenia | 10 Jul 2015 | 19 May 2017 | 1.9 y | 1 Oct 2017 | 2.2 y |
| CariprazineReagila (Vraylar in the US) · Schizophrenia | 17 Sept 2015 | 18 Nov 2020 | 5.2 y | 1 Sept 2021 | 6.0 y |
| EsketamineSpravato · Treatment-resistant depression | 5 Mar 2019 | 9 Mar 2021 | 2.0 y | 1 May 2025 | 6.2 y |
| BrexanoloneZulresso · Postpartum depression | 19 Mar 2019 | No entry found | none after 7.7 y | Not listed | – |
| LumateperoneCaplyta · Schizophrenia | 20 Dec 2019 | No entry found | none after 6.9 y | Not listed | – |
| LemborexantDayvigo · Insomnia | 20 Dec 2019 | 16 Jul 2021 | 1.6 y | Not checked | – |
| DaridorexantQuviviq · Insomnia | 7 Jan 2022 | No entry found | none after 4.9 y | Not listed | – |
| Dextromethorphan-bupropionAuvelity · Major depressive disorder | 18 Aug 2022 | No entry found | none after 4.3 y | Not listed | – |
| ZuranoloneZurzuvae · Postpartum depression | 4 Aug 2023 | No entry found | none after 3.3 y | Not listed | – |
| GepironeExxua · Major depressive disorder | 22 Sept 2023 | No entry found | none after 3.2 y | Not listed | – |
| Xanomeline-trospiumCobenfy · Schizophrenia | 26 Sept 2024 | No entry found | none after 2.1 y | Not listed | – |
Open questions
A public ledger of yes-or-no questions about regulatory records. Each states now how it will be settled, and the base rate that applies with its arithmetic. Entries are appended and never edited. This site does not publish probabilities for these questions; it shows the base rate only.
Will a psilocybin medicine be entered on the Australian Register of Therapeutic Goods by 31 December 2028?
- Resolves by
- · Registration
- How it will be settled
- Yes if a search of the ARTG on the TGA website on 1 January 2029 shows a registered medicine whose active ingredient is psilocybine, with an ARTG date on or before 31 December 2028. Otherwise no.
- Base rate
- 23% 3 of 13 comparator medicines were on the ARTG within 2 years of FDA approval (3 / 13 = 23%). The window here ends about 2 years after the earliest date the FDA could decide, and the FDA has not decided.
Will an MDMA medicine be entered on the Australian Register of Therapeutic Goods by 31 December 2029?
- Resolves by
- · Registration
- How it will be settled
- Yes if a search of the ARTG on the TGA website on 1 January 2030 shows a registered medicine whose active ingredient is MDMA (midomafetamine), with an ARTG date on or before 31 December 2029. Otherwise no.
- Base rate
- 23% 3 of 13 comparator medicines were on the ARTG within 2 years of FDA approval (3 / 13 = 23%). The FDA has not approved an MDMA medicine, so the clock has not started.
Will the FDA approve a new drug application for a psilocybin medicine by 31 December 2027?
- Resolves by
- · Registration
- How it will be settled
- Yes if Drugs@FDA shows an original approval, dated on or before 31 December 2027, for a product whose active ingredient is psilocybin. Otherwise no.
- Base rate
- 50% FDA decisions recorded in the milestones table for psychedelic or closely related medicines: esketamine approved (2019), midomafetamine not approved (2024). 1 of 2 = 50%. Two cases are too few to lean on.
Will the FDA approve a new drug application for an MDMA medicine by 31 December 2028?
- Resolves by
- · Registration
- How it will be settled
- Yes if Drugs@FDA shows an original approval, dated on or before 31 December 2028, for a product whose active ingredient is midomafetamine (MDMA). Otherwise no.
- Base rate
- 50% FDA decisions recorded in the milestones table for psychedelic or closely related medicines: esketamine approved (2019), midomafetamine not approved (2024). 1 of 2 = 50%. Two cases are too few to lean on.
Will the TGA publish a final decision that changes the Poisons Standard entry for psilocybine or MDMA by 31 December 2027?
- Resolves by
- · Scheduling
- How it will be settled
- Yes if the TGA publishes, on or before 31 December 2027, a notice of final decision to amend the Poisons Standard that changes the schedule entry or the Appendix D entry for psilocybine or MDMA. Interim decisions, and final decisions not to amend, count as no.
- Base rate
- 20% One amending final decision for these entries is known to this site between 1 January 2022 and 20 November 2026 (announced 3 February 2023): 1 in 4.9 years, about 0.2 a year. Over the 1.1 years left, 1 - exp(-0.2 x 1.1) = 20%.
Will the TGA report more than 100 active Authorised Prescribers for psilocybine at a date on or before 31 December 2027?
- Resolves by
- · Access scheme
- How it will be settled
- Yes if a TGA publication (web page, report or freedom of information release) gives a count of active Authorised Prescribers for psilocybine above 100 as at any date on or before 31 December 2027. Decided on the figures published by 30 June 2028. If the TGA publishes no count dated after 18 August 2026, the question is annulled.
- Base rate
- None stated No count-based rate: there is one series. It went from 0 on 1 July 2023 to 61 on 18 August 2026, about 19.5 a year. A straight line reaches about 88 by 31 December 2027 (61 + 19.5 x 1.37), below 100.
Will a psilocybin or MDMA therapy be recommended for PBS or MBS funding by 31 December 2029?
- Resolves by
- · Subsidy
- How it will be settled
- Yes if, on or before 31 December 2029, PBAC outcomes published on pbs.gov.au record a recommendation to list a psilocybin or MDMA medicine, or the MSAC website records support for public funding of a service that delivers psilocybin- or MDMA-assisted therapy. Otherwise no.
- Base rate
- 11% 1 of 9 comparator medicines with a known PBS status and at least 3 years since FDA approval was PBS-listed within 3 years of that approval (1 / 9 = 11%). Three years is roughly the window left after the earliest possible FDA decision. Listing follows a recommendation by some months, so this slightly understates recommendations.
Track record
Nothing has resolved yet. 7 questions are open; the first falls due on 31 December 2027. When questions resolve, this block will show how many resolved, the Brier score of any published probabilities, and the Brier score the base rates alone would have earned.
A Brier score is the average squared gap between a stated probability and what happened: 0 is perfect, 0.25 is what saying 50% every time earns.
Limits
- The reference class is small: 13 medicines, 6 of them registered in Australia. One more registration would move every figure here.
- A base rate describes what happened to a group of earlier medicines. It is not a forecast of any single decision, which turns on its own evidence and its sponsor's choices.
- Scheduling, registration and subsidy are separate decisions made under separate rules. Australia's early move on scheduling says nothing about the timing of the other two.
- Every row is maintained by hand. Each source shows the date it was last opened; a fact can change after that date.
- The PBS status of three registered comparators (vortioxetine, suvorexant, lemborexant) has not been checked against a primary source, so they are left out of the PBS figures.